<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05112653</url>
  </required_header>
  <id_info>
    <org_study_id>AssiutU2021</org_study_id>
    <nct_id>NCT05112653</nct_id>
  </id_info>
  <brief_title>Value of MicroRNA30a in Philadelphia Positive Leukemic Patients</brief_title>
  <official_title>Value of MicroRNA30a in Philadelphia Positive Leukemic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Philadelphia chromosome in leukemogenesis:The truncated chromosome 22 that results from&#xD;
      the reciprocal translocation t(9;22)(q34;q11) is known as (Ph) and is a hallmark of (CML).&#xD;
      This aberrant fusion gene encodes the breakpoint cluster region-proto-(BCR-ABL1) oncogenic&#xD;
      protein with persistently enhanced tyrosine kinase activity. Besides CML, the Ph is found in&#xD;
      acute lymphoblastic leukemia, and mixed-phenotype acute leukemia.&#xD;
&#xD;
      Chronic myeloid leukemia is a myeloproliferative neoplasm, characterized by the unrestrained&#xD;
      expansion of pluripotent bone marrow stem cells.The hallmark of the disease is the presence&#xD;
      of a reciprocal t(9;22)(q34;q11.2), resulting in a derivative 9q+ and a small 22q-. The&#xD;
      latter, known as the Philadelphia chromosome, results in a BCR-ABL fusion gene . The&#xD;
      diagnosis requires fluorescent in situ hybridization (to demonstrate the BCR-ABL fusion gene&#xD;
      or(PCR) to demonstrate the BCR-ABL mRNA transcript.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      our study will discuss the possible value of microRNA30a as early predictor for TKIs&#xD;
      resistance in newly diagnosed CML patients.&#xD;
&#xD;
      the study will dectect the possible value of microRNA30a as prognostic marker in Philadelphia&#xD;
      positive acute leukemic patients(ALL, mixed-phenotype acute leukemia) on TKI therapy by&#xD;
      assessment level of microRNA30a inpatients who achieved complete hematological remission(CHR)&#xD;
      and who failed to achieve CHR.&#xD;
&#xD;
      The study goal has been taken through the role of microRNA30a in reducing ABL1 and BCR-ABL1&#xD;
      protein expression and microRNAs are capable of changing the levels of several key proteins&#xD;
      at various steps of the autophagic pathway.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2022</start_date>
  <completion_date type="Anticipated">December 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To detect the possibility of using microRNA30a as a prognostic marker in Philadelphia Positive Leukemic Patients by measure level of microRNA30a in blood sample of Philadelphia positive leukemic patients on tyrosine kinase inhibitor therapy</measure>
    <time_frame>2 years</time_frame>
    <description>The study goal has been taken through the role of microRNA30a in reducing ABL1 and BCR-ABL1 protein expression and microRNAs are capable of changing the levels of several key proteins at various steps of the autophagic pathway.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Possibility of Using microRNA30a as a Prognostic Marker in Philadelphia Positive Leukemic Patients by Measure Level of microRNA30a in Blood Sample</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>Group of Philadelphia positive leukemic patients will included in the study who divide into:&#xD;
patient newly diagnosed CML treated with first line of tyrosine kinase inhibitors therapy.&#xD;
Philadelphia positive acute leukemic patients(ALL, mixed-phenotype acute leukemia) on TKI therapy who achieved complete hematological remission(CHR) and who failed to achieve CHR.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        70 patients diagnosed as Philadelphia positive leukemic patients(CML, acute lymphoblastic&#xD;
        leukemia, and mixed-phenotype acute leukemia).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        3 a-Inclusion criteria&#xD;
&#xD;
        1_clinical diagnosis of Philadelphia positive leukemic patients (males and females).&#xD;
&#xD;
        2- Aged from 18- 60 years. 3-All eligible patients presenting at Clinical Haematology Unit&#xD;
        Internal Medicine Department.&#xD;
&#xD;
        4- Without contraindication to receive TKIs therapy. 5-Must able to swallow tablet(TKI&#xD;
        therapy).&#xD;
&#xD;
        -exclusion criteria&#xD;
&#xD;
          1. NO bone marrow aspirate and flow cytometry confirm their diagnosis.&#xD;
&#xD;
          2. patients who refuse to participate in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>more in males</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
  </eligibility>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 10, 2021</study_first_submitted>
  <study_first_submitted_qc>November 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2021</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Hager mohammed</investigator_full_name>
    <investigator_title>assuit university</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

